CTDNEP1 and neoplasm: To examine MYC stability, we treated tumor cells with a protein synthesis inhibitor cycloheximide (CHX) and found that both MYC and p-S62-MYC levels remained higher in the MYC-amplified D425 and non-MYC amplified D283 cells with CTDNEP1 knockdown than control-treated cells (Fig. 3f and Supplementary Fig. 5b, c).